GeneDx (NASDAQ: WGS) recently received a number of ratings updates from brokerages and research firms:
- 11/18/2026 – GeneDx had its “buy” rating reaffirmed by BTIG Research. They now have a $85.00 price target on the stock.
- 11/16/2026 – GeneDx was upgraded by Zacks Research from “hold” to “strong-buy”.
- 11/10/2026 – GeneDx had its “buy” rating reaffirmed by BTIG Research. They now have a $85.00 price target on the stock, down from $90.00.
- 11/2/2026 – GeneDx had its “sell (d)” rating reaffirmed by Weiss Ratings.
- 10/9/2026 – GeneDx was downgraded by Zacks Research from “strong-buy” to “hold”.
- 10/1/2026 – GeneDx had its price target raised by Guggenheim from $74.00 to $83.00. They now have a “buy” rating on the stock.
GeneDx Price Performance
NASDAQ:WGS traded up $4.67 during trading hours on Wednesday, reaching $51.96. The company had a trading volume of 1,710,385 shares, compared to its average volume of 948,984. The company has a quick ratio of 3.85, a current ratio of 4.16 and a debt-to-equity ratio of 0.60. The stock has a 50-day moving average of $72.36 and a two-hundred day moving average of $69.72. GeneDx Holdings Corp. has a one year low of $32.21 and a one year high of $170.87. The firm has a market capitalization of $1.56 billion, a PE ratio of -13.75 and a beta of 2.00.
GeneDx (NASDAQ:WGS – Get Free Report) last issued its quarterly earnings data on Monday, November 9th. The company reported $0.28 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.07 by $0.21. GeneDx had a positive return on equity of 1.98% and a negative net margin of 24.10%. The company had revenue of $123.10 million during the quarter, compared to analysts’ expectations of $122.93 million. During the same period last year, the business earned ($0.27) earnings per share. Analysts forecast that GeneDx Holdings Corp. will post -0.41 earnings per share for the current year.
Insider Activity
GeneDx is a genomic testing company focused on helping clinicians diagnose rare and inherited conditions. Its services include whole exome and whole genome sequencing, along with other genetic tests and clinical interpretation of results. The company’s testing is used by healthcare providers to support diagnosis and care decisions, particularly for patients with suspected rare genetic disorders. GeneDx also offers testing related to hereditary cancer risk. Founded in 2000 by researchers with experience at the National Institutes of Health, GeneDx has developed its business around applying genomic information in clinical care.
Featured Stories
- Five stocks we like better than GeneDx
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
- Viking’s Low-Water Miss Looks Like a Buy-the-Dip Opportunity
- Why Amazon Wants the Chips and Blackstone Wants the Buildings
Receive News & Ratings for GeneDx Holdings Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GeneDx Holdings Corp and related companies with MarketBeat.com's FREE daily email newsletter.
